本文選題：骨趨化因子受體 + 補益中藥　； 參考：《中國中西醫(yī)結(jié)合雜志》2017年05期

【摘要】：目的觀察不同歸經(jīng)補益中藥對骨轉(zhuǎn)移癌骨趨化因子受體4(CXCR4)的抑制及機制。方法采用轉(zhuǎn)移性大鼠乳腺癌細(xì)胞,按Medhurst方法復(fù)制骨轉(zhuǎn)移癌模型。40只大鼠按照體重分層,采用隨機數(shù)字表法分為假手術(shù)組、模型組、腎經(jīng)組、肺經(jīng)組和肝經(jīng)組,每組8只。造模后腎經(jīng)組(補骨脂、肉蓯蓉及益智仁)、肝經(jīng)組(熊膽粉)、肺經(jīng)組(黨參、黃芪及百合)給藥量為10 mL/(kg·d),相當(dāng)于生藥45 g/(kg·d)灌胃,假手術(shù)組及模型組給予去離子水灌胃,持續(xù)20天。觀察不同歸經(jīng)補益中藥的作用,通過影像學(xué)方法進(jìn)行評分、測量腫瘤體積,HE染色觀察形態(tài),免疫組化法檢測CXCR4表達(dá)并進(jìn)行半定量分析。結(jié)果骨轉(zhuǎn)移癌模型出現(xiàn)骨質(zhì)破壞和腫瘤生長等表現(xiàn)。與假手術(shù)組比較,模型組腫瘤體積增大(P0.01),模型組骨質(zhì)破壞嚴(yán)重,評分升高(P0.01),CXCR4表達(dá)升高(P0.01)。與模型組比較,腎經(jīng)組腫瘤體積縮小(P0.05),骨質(zhì)破壞明顯減輕,評分降低(P0.05),CXCR4表達(dá)明顯下降(P0.01);肺經(jīng)組和肝經(jīng)組上述指標(biāo)與模型組比較,差異均無統(tǒng)計學(xué)意義(P0.05)。結(jié)論歸腎經(jīng)中藥對骨轉(zhuǎn)移癌灶的生長具有一定的抑制作用,其機制可能通過阻斷SDF-1/CXCR4生物學(xué)軸及下游信號通路,達(dá)到抗腫瘤定向侵襲和增殖的目的。歸肺經(jīng)、歸肝經(jīng)藥物不存在類似作用,不同歸經(jīng)中藥對機體的作用存在靶向特異性。
[Abstract]:Objective to observe the inhibition of CXCR4 on bone chemokine receptor 4 (CXCR4) in patients with bone metastases. Methods the metastatic rat breast cancer cells were used. According to Medhurst's method, 40 rats were divided into sham-operation group, model group, renal meridian group, lung meridian group and liver meridian group with 8 rats in each group. The dosage of 10 mL / (kg d), in kidney meridian group (psoralen, Cistanche deserticola and Yizhiren), liver meridian group (bear gallbladder powder) and lung meridian group (Codonopsis pilosula, astragalus membranaceus and lily) was equivalent to 45 g / (kg d) of raw medicine, and the sham operation group and model group were given deionized water. It lasts for 20 days. The effects of different meridians and tonifying herbs were observed, the tumor volume was measured by HE staining, the expression of CXCR4 was detected by immunohistochemistry and semi-quantitative analysis was carried out. Results Bone destruction and tumor growth were found in the model of bone metastases. Compared with the sham-operated group, the tumor volume in the model group increased (P0.01), the bone destruction was serious in the model group, and the expression of CXCR4 in the model group was increased (P0.01). Compared with the model group, the tumor volume of kidney meridian group was reduced (P0.05), bone destruction was alleviated significantly, and the score decreased (P0.05). The expression of CXCR4 in lung meridian group and liver meridian group was significantly lower than that in model group (P0.01). There was no significant difference between lung meridian group and liver meridian group compared with model group (P0.05). Conclusion Guishen meridian has a certain inhibitory effect on the growth of bone metastases, and its mechanism may be through blocking the biological axis and downstream signal pathway of SDF-1 / CXCR4 to achieve the purpose of anti-tumor directed invasion and proliferation. There is no similar effect in Gui Fei meridian and Guigan meridian drugs, but there is a target specificity in the effect of different Gui Jing traditional Chinese medicine on the body.
【作者單位】： 中國中醫(yī)科學(xué)院望京醫(yī)院腫瘤科;
【基金】：國家自然科學(xué)基金資助項目(No.81173374)
【分類號】：R273

【相似文獻(xiàn)】

相關(guān)期刊論文 前9條

1 劉傳波;李泉旺;姜敏;左明煥;孫韜;;骨轉(zhuǎn)移癌的中醫(yī)藥研究進(jìn)展[J];江蘇中醫(yī)藥;2010年04期

2 王瑞中;;三處骨轉(zhuǎn)移癌現(xiàn)生存六年一例報告[J];河北中醫(yī);1980年02期

3 李學(xué)，，黃志高;76例骨轉(zhuǎn)移癌的臨床特點分析[J];中醫(yī)研究;1996年06期

4 潘婉;李航森;;二骨散加減配合天晴依泰治療骨轉(zhuǎn)移癌的療效觀察[J];湖北中醫(yī)雜志;2009年05期

5 馮宇;崔藝馨;徐睿鑫;姜淼;;中醫(yī)藥治療骨轉(zhuǎn)移癌研究進(jìn)展[J];環(huán)球中醫(yī)藥;2014年08期

6 牛維,吳萬垠;骨轉(zhuǎn)移癌的中醫(yī)藥治療進(jìn)展[J];中醫(yī)研究;2001年02期

7 關(guān)新軍;王婭玲;;骨轉(zhuǎn)移癌的病因病機探討[J];中國中醫(yī)基礎(chǔ)醫(yī)學(xué)雜志;2009年03期

8 沈建平;甲骨湯合消瘤丸辨證治療骨轉(zhuǎn)移癌100例[J];南京中醫(yī)藥大學(xué)學(xué)報;1997年04期

9 ;[J];;年期

相關(guān)會議論文 前1條

1 馮利;閆秀峰;王芳;何生奇;楊霖;黃科;;益腎骨康湯改善腫瘤骨轉(zhuǎn)移癌患者生存質(zhì)量臨床研究[A];2009年首屆全國中西醫(yī)腫瘤博士及中青年醫(yī)師論壇論文集[C];2009年

相關(guān)重要報紙文章 前1條

1 蔡悅成 葉金輝;放療加復(fù)方苦參注射液治療骨轉(zhuǎn)移癌的臨床研究[N];中國中醫(yī)藥報;2006年

相關(guān)碩士學(xué)位論文 前7條

1 潘婉;二骨散加減聯(lián)合天晴依泰治療骨轉(zhuǎn)移癌綜合療效的臨床觀察[D];湖北中醫(yī)學(xué)院;2009年

2 趙嫻;肺癌不同中醫(yī)證型與骨轉(zhuǎn)移關(guān)系的初步探討[D];廣州中醫(yī)藥大學(xué);2008年

3 林荔欽;不同歸經(jīng)補益方劑治療骨轉(zhuǎn)移癌的機理研究[D];北京中醫(yī)藥大學(xué);2014年

4 原苗苗;骨瘤康顆粒治療腎精虧虛型骨轉(zhuǎn)移癌及其對血清BSP的影響[D];河南中醫(yī)學(xué)院;2014年

5 謝聰;骨瘤康顆粒聯(lián)合唑來膦酸對腎虛痰凝型骨轉(zhuǎn)移癌的療效觀察以及對尿NTx水平影響的研究[D];河南中醫(yī)學(xué)院;2014年

6 陳顯;護骨消積方治療骨轉(zhuǎn)移癌的療效及NTX與腎虛證型的研究[D];廣州中醫(yī)藥大學(xué);2014年

7 包烏吉斯古冷;前列腺癌骨轉(zhuǎn)移中醫(yī)證型及證素分布的研究[D];北京中醫(yī)藥大學(xué);2013年

本文編號：2069982